FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer

    NEXT STORY
    AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
    PREV STORY
    Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    VBL Therapeutics to Report First Quarter 2016 Financial Results on May 13

    TEL AVIV, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

    author_avatar
    NASDAQ Market News

    Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update

    NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), ...

    author_avatar
    NASDAQ Market News